MiRNA profiling in pancreatic cancer and restoration of chemosensitivity

Cancer Letters

Volumn 334, Issue 2, 2013, Pages 211-220

  Singh, Saurabh ^a   Chitkara, Deepak ^a,b   Kumar, Virender ^a   Behrman, Stephen W ^a   Mahato, Ram I ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Cancer stem cells; Chemoresistance; Gemcitabine; MiRNA; Pancreatic cancer

Indexed keywords

ALCOHOL DEHYDROGENASE; BETA TUBULIN; CLASS III BETA TUBULIN; GEMCITABINE; HERMES ANTIGEN; MICRORNA; MICRORNA 146; MICRORNA 205; MICRORNA 7; OCTAMER TRANSCRIPTION FACTOR 4; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER STEM CELL; CANCER TISSUE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; PANCREAS CANCER; PRIORITY JOURNAL; UPREGULATION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS;

AGOUTI PACA;

EID: 84878214589     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.10.008     Document Type: Article

References (68)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2012, 62:10-29.
2. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., Nelson R., Dorr F.A., Stephens C.D., Von Hoff D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15:2403-2413.
3. Wong A., Soo R.A., Yong W.P., Innocenti F. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab. Rev. 2009, 41:77-88.
4. Beumer J.H., Eiseman J.L., Parise R.A., Joseph E., Covey J.M., Egorin M.J. Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine. Clin. Cancer Res. 2008, 14:3529-3535.
5. Siegel R., Desantis C., Virgo K., Stein K., Mariotto A., Smith T., Cooper D., Gansler T., Lerro C., Fedewa S., Lin C., Leach C., Cannady R.S., Cho H., Scoppa S., Hachey M., Kirch R., Jemal A., Ward E. Cancer treatment and survivorship statistics. CA Cancer J. Clin. 2012, 62:220-241.
6. Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65:10946-10951.
7. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
8. Vira D., Basak S.K., Veena M.S., Wang M.B., Batra R.K., Srivatsan E.S. Cancer stem cells, microRNAs, and therapeutic strategies including natural products. Cancer Metastasis Rev. 2012, 31:733-751.
9. Cittelly D.M., Finlay-Schultz J., Howe E.N., Spoelstra N.S., Axlund S.D., Hendricks P., Jacobsen B.M., Sartorius C.A., Richer J.K. Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. Oncogene 2012, 1-10.
10. Wang L., Zhang D., Zhang C., Zhang S., Wang Z., Qu C., Liu S. A microRNA expression signature characterizing the properties of tumor-initiating cells for breast cancer. Oncol. Lett. 2012, 3:119-124.
11. Liu C., Kelnar K., Vlassov A.V., Brown D., Wang J., Tang D.G. Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. Cancer Res. 2012, 72:3393-3404.
12. Li W.G., Yuan Y.Z., Qiao M.M., Zhang Y.P. High dose glargine alters the expression profiles of microRNAs in pancreatic cancer cells. World J. Gastroenterol. 2012, 18:2630-2639.
13. Kent O.A., Mendell J.T. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 2006, 25:6188-6196.
14. Sarkar F.H., Li Y., Wang Z., Kong D., Ali S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist. Update. 2010, 13:57-66.
15. Zhang W., Dahlberg J.E., Tam W. MicroRNAs in tumorigenesis: a primer. Am. J. Pathol. 2007, 171:728-738.
16. Singh S., Chitkara D., Mehrazin R., Behrman S.W., Wake R.W., Mahato R.I. Chemoresistance in prostate cancer cells is regulated by miRNAs and hedgehog pathway. PLoS One 2012, 7:e40021.
17. Douville J., Beaulieu R., Balicki D. ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev. 2009, 18:17-25.
18. Muzio G., Maggiora M., Paiuzzi E., Oraldi M., Canuto R.A. Aldehyde dehydrogenases and cell proliferation. Free Radical Biol. Med. 2012, 52:735-746.
19. Ma I., Allan A.L. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cells Rev. 2011, 7:292-306.
20. Greve B., Kelsch R., Spaniol K., Eich H.T., Gotte M. Flow cytometry in cancer stem cell analysis and separation. Cytometry A 2012, 81:284-293.
21. Rasheed Z.A., Matsui W. Biological and clinical relevance of stem cells in pancreatic adenocarcinoma. J. Gastroenterol. Hepatol. 2012, 27(Suppl 2):15-18.
22. Stratford E.W., Castro R., Wennerstrom A., Holm R., Munthe E., Lauvrak S., Bjerkehagen B., Myklebost O. Liposarcoma cells with aldefluor and CD133 activity have a cancer stem cell potential. Clin. Sarcoma Res. 2011, 1:8.
23. Alla V., Kowtharapu B.S., Engelmann D., Emmrich S., Schmitz U., Steder M., Putzer B.M. E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle 2012, 11:3067-3078.
24. Allen J.D., Van Dort S.C., Buitelaar M., van Tellingen O., Schinkel A.H. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res. 2003, 63:1339-1344.
25. Cufi S., Corominas-Faja B., Vazquez-Martin A., Oliveras-Ferraros C., Dorca J., Bosch-Barrera J., Martin-Castillo B., Menendez J.A. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget 2012, 3:395-398.
26. Han J., Zhang F., Yu M., Zhao P., Ji W., Zhang H., Wu B., Wang Y., Niu R. RNA interference-mediated silencing of NANOG reduces cell proliferation and induces G0/G1 cell cycle arrest in breast cancer cells. Cancer Lett. 2012, 321:80-88.
27. Ho M.M., Ng A.V., Lam S., Hung J.Y. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007, 67:4827-4833.
28. Cochrane D.R., Howe E.N., Spoelstra N.S., Richer J.K. Loss of miR-200c: a marker of aggressiveness and chemoresistance in female reproductive cancers. J. Oncol. 2010, 2010:821717.
29. Reddy S.D., Ohshiro K., Rayala S.K., Kumar R. MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res. 2008, 68:8195-8200.
30. Ahrendt S.A., Pitt H.A. Surgical management of pancreatic cancer. Oncology 2002, 16:725-734. (discussion 734, 736-728, 740, 743).
31. Arumugam T., Ramachandran V., Fournier K.F., Wang H., Marquis L., Abbruzzese J.L., Gallick G.E., Logsdon C.D., McConkey D.J., Choi W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009, 69:5820-5828.
32. Bailey J.M., Swanson B.J., Hamada T., Eggers J.P., Singh P.K., Caffery T., Ouellette M.M., Hollingsworth M.A. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin. Cancer Res. 2008, 14:5995-6004.
33. Saur D., Seidler B., Schneider G., Algul H., Beck R., Senekowitsch-Schmidtke R., Schwaiger M., Schmid R.M. CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer. Gastroenterology 2005, 129:1237-1250.
34. Singh A., Settleman J. EMT, cancer stem cells and drug resistance. an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741-4751.
35. Lengerke C., Fehm T., Kurth R., Neubauer H., Scheble V., Muller F., Schneider F., Petersen K., Wallwiener D., Kanz L., Fend F., Perner S., Bareiss P.M., Staebler A. Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma. BMC Cancer 2011, 11:42.
36. Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F., Hilsenbeck S.G., Pavlick A., Zhang X., Chamness G.C., Wong H., Rosen J., Chang J.C. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 2008, 100:672-679.
37. Wang Y.C., Yo Y.T., Lee H.Y., Liao Y.P., Chao T.K., Su P.H., Lai H.C. ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome. Am. J. Pathol. 2012, 180:1159-1169.
38. Kurebayashi J., Kanomata N., Shimo T., Yamashita T., Aogi K., Nishimura R., Shimizu C., Tsuda H., Moriya T., Sonoo H. Marked lymphovascular invasion progesterone receptor negativity and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone. Breast Cancer 2012, 1-9.
39. Kim M.P., Fleming J.B., Wang H., Abbruzzese J.L., Choi W., Kopetz S., McConkey D.J., Evans D.B., Gallick G.E. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One 2011, 6:e20636.
40. Moreb J., Schweder M., Suresh A., Zucali J.R. Overexpression of the human aldehyde dehydrogenase class I results in increased resistance to 4-hydroperoxycyclophosphamide. Cancer Gene Ther. 1996, 3:24-30.
41. Jimeno A., Feldmann G., Suarez-Gauthier A., Rasheed Z., Solomon A., Zou G.M., Rubio-Viqueira B., Garcia-Garcia E., Lopez-Rios F., Matsui W., Maitra A., Hidalgo M. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol. Cancer Ther. 2009, 8:310-314.
42. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., Campbell L.L., Polyak K., Brisken C., Yang J., Weinberg R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
43. Pan J.J., Yang M.H. The role of epithelial-mesenchymal transition in pancreatic cancer. J. Gastrointest Oncol. 2011, 2:151-156.
44. Yao J., Cai H.H., Wei J.S., An Y., Ji Z.L., Lu Z.P., Wu J.L., Chen P., Jiang K.R., Dai C.C., Qian Z.Y., Xu Z.K., Miao Y. Side population in the pancreatic cancer cell lines SW1990 and CFPAC-1 is enriched with cancer stem-like cells. Oncol. Rep. 2010, 23:1375-1382.
45. Han J., Zhang F., Yu M., Zhao P., Ji W., Zhang H., Wu B., Wang Y., Niu R. RNA interference-mediated silencing of NANOG reduces cell proliferation and induces G0/G1 cell cycle arrest in breast cancer cells. Cancer Lett. 2012, 325:80-88.
46. Bao B., Wang Z., Ali S., Ahmad A., Azmi A.S., Sarkar S.H., Banerjee S., Kong D., Li Y., Thakur S., Sarkar F.H. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev. Res. (Phila) 2012, 5:355-364.
47. Peacock C.D., Wang Q., Gesell G.S., Corcoran-Schwartz I.M., Jones E., Kim J., Devereux W.L., Rhodes J.T., Huff C.A., Beachy P.A., Watkins D.N., Matsui W. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc. Natl. Acad Sci. USA 2007, 104:4048-4053.
48. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
49. Kim M., Turnquist H., Jackson J., Sgagias M., Yan Y., Gong M., Dean M., Sharp J.G., Cowan K. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin. Cancer Res. 2002, 8:22-28.
50. Rudin D., Li L., Niu N., Kalari K.R., Gilbert J.A., Ames M.M., Wang L. Gemcitabine cytotoxicity: interaction of efflux and deamination. J. Drug Metab. Toxicol. 2011, 2:1-10.
51. Mimeault M., Johansson S.L., Henichart J.P., Depreux P., Batra S.K. Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells. Mol. Cancer Ther. 2010, 9:617-630.
52. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., Bruns C.J., Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
53. Singh S., Chitkara D., Mehrazin R., Behrman S.W., Wake R.W., Mahato R.I. Chemoresistance in prostate cancer cells is regulated by miRNAs and hedgehog pathway. PLoS ONE 2012, 7:e40021.
54. Ali S., Ahmad A., Banerjee S., Padhye S., Dominiak K., Schaffert J.M., Wang Z., Philip P.A., Sarkar F.H. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 2010, 70:3606-3617.
55. Park J.K., Lee E.J., Esau C., Schmittgen T.D. Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas 2009, 38:e190-199.
56. Childs G., Fazzari M., Kung G., Kawachi N., Brandwein-Gensler M., McLemore M., Chen Q., Burk R.D., Smith R.V., Prystowsky M.B., Belbin T.J., Schlecht N.F. Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am. J. Pathol. 2009, 174:736-745.
57. Li Y., VandenBoom T.G., Kong D., Wang Z., Ali S., Philip P.A., Sarkar F.H. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009, 69:6704-6712.
58. Tellez C.S., Juri D.E., Do K., Bernauer A.M., Thomas C.L., Damiani L.A., Tessema M., Leng S., Belinsky S.A. EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res. 2011, 71:3087-3097.
59. Zhang H.L., Ruan L., Zheng L.M., Whyte D., Tzeng C.M., Zhou X.W. Association between class III beta-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer 2012, 77:9-15.
60. Hirai Y., Yoshimasu T., Oura S., Ota F., Naito K., Nishiguchi H., Hashimoto S., Okamura Y. Is class III beta-tubulin a true predictive marker of sensitivity to vinorelbine in non-small cell lung cancer? Chemosensitivity data evidence. Anticancer Res. 2011, 31:999-1005.
61. Vilmar A.C., Santoni-Rugiu E., Sorensen J.B. Class III beta-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial. Clin. Cancer Res. 2011, 17:5205-5214.
62. Xu Y., Brenn T., Brown E.R., Doherty V., Melton D.W. Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors. Brit. J. Cancer 2012, 106:553-561.
63. Hulf T., Sibbritt T., Wiklund E.D., Patterson K., Song J.Z., Stirzaker C., Qu W., Nair S., Horvath L.G., Armstrong N.J., Kench J.G., Sutherland R.L., Clark S.J. Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer. Oncogene 2012, 1-9.
64. Boll K., Reiche K., Kasack K., Morbt N., Kretzschmar A.K., Tomm J.M., Verhaegh G., Schalken J., von Bergen M., Horn F., Hackermuller J. MiR-130a miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene 2012, 1-9.
65. Gandellini P., Profumo V., Casamichele A., Fenderico N., Borrelli S., Petrovich G., Santilli G., Callari M., Colecchia M., Pozzi S., De Cesare M., Folini M., Valdagni R., Mantovani R., Zaffaroni N. miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. Cell Death Differ. 2012, 19:1750-1760.
66. Zhou W., Kallifatidis G., Baumann B., Rausch V., Mattern J., Gladkich J., Giese N., Moldenhauer G., Wirth T., Buchler M.W., Salnikov A.V., Herr I. Dietary polyphenol quercetin targets pancreatic cancer stem cells. Int. J. Oncol. 2010, 37:551-561.
67. Esquela-Kerscher A., Trang P., Wiggins J.F., Patrawala L., Cheng A., Ford L., Weidhaas J.B., Brown D., Bader A.G., Slack F.J. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008, 7:759-764.
68. Danquah M., Singh S., Behrman S.W., Mahato R.I. Role of miRNA and cancer stem cells in chemoresistance and pancreatic cancer treatment. Expert Opin. Drug. Deliv. 2012.